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Tumors abuse myeloid plasticity to re-direct dendritic cell (DC) differentiation from T cell
stimulatory subsets to immune-suppressive subsets that can interfere with anti-tumor
immunity. Lined by a dense network of easily accessible DC the skin is a preferred site
for the delivery of DC-targeted vaccines. Various groups have recently been focusing on
functional aspects of DC subsets in the skin and how these may be affected by tumor-
derived suppressive factors. IL-6, Prostaglandin-E2, and IL-10 were identified as factors in
cultures of primary human tumors responsible for the inhibited development and activation
of skin DC as well as monocyte-derived DC. IL-10 was found to be uniquely able to convert
fully developed DC to immature macrophage-like cells with functional M2 characteristics
in a physiologically highly relevant skin explant model in which the phenotypic and func-
tional traits of “crawl-out” DC were studied. Mostly from mouse studies, the JAK2/STAT3
signaling pathway has emerged as a “master switch” of tumor-induced immune suppres-
sion. Our lab has additionally identified p38-MAPK as an important signaling element in
human DC suppression, and recently validated it as such in ex vivo cultures of single-cell
suspensions from melanoma metastases. Through the identification of molecular mech-
anisms and signaling events that drive myeloid immune suppression in human tumors,
more effective DC-targeted cancer vaccines may be designed.
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DENDRITIC CELL SUBSETS AND THEIR PLASTICITY IN
HUMAN SKIN: IMPACT ON CANCER VACCINATION
Skin is the largest human organ and its direct contact with
the outside environment requires tightly regulated surveillance
mechanisms to keep potentially harmful intruders at bay. For
this purpose, human skin is densely populated with patrolling
myeloid cells, such as Langerhans cells (LC) in the epidermal
outer layer and various dermal dendritic cell (DDC) subsets and
macrophages in the dermal layer (1, 2). It has been elegantly
shown that different profiles of pattern recognition receptors
present on the various myeloid subsets lining the skin makes
them exquisitely specific in the recognition, uptake and either
direct elimination of pathogenic microbes, or in presentation
of pathogen-associated antigens for subsequent activation of the
adaptive immune system (3–5). Interaction of a pathogen with
pathogen-recognition receptors on dendritic cell (DC) induces
activation of down-stream signaling pathways that result in their
enhanced ability to process and present pathogenic antigens and
in their migration to the draining lymph nodes, accompanied
by phenotypic and morphological maturation, and priming of
antigen-specific T or B lymphocytes (6). Whereas initially studies
concerning DC subsets in human skin mostly involved the most
predominant subsets, i.e., CD1ahiLangerin+ LC, CD1a+ DDC,
and CD14+CD1a−DDC (7–9), the characterization of new surface
markers and deeper phenotypic and functional analyses now show
that further distinctions can be made (10–13).
From our own work and that of others, it has become clear that
beside epidermal LC and dermal macrophages at least five migra-
tory DDC subsets can be distinguished (13, 14), i.e.,CD1a+CD14−
DDC,CD1a+CD14+DDC,CD1a−CD14+DDC,and two double-
negative subsets. An important issue that as yet remains unresolved
is whether all these DC populations represent genuine subsets, or
whether they are part of the same DC subset in various states of
activation or differentiation. A growing number of studies now
point to the existence of an inter-related population of cutaneous
DC and macrophages in flux, trans-differentiating into each other
as directed by environmental cues (8, 15, 16). This has direct con-
sequences for the type of immune responses that will ensue, as
different migratory DC sub-populations have now been directly
linked to the induction of different types of immunity (13, 14) and
have different capacities to cross-present antigens for the activa-
tion of cytotoxic CD8 T cells, a process crucial for the induction of
anti-tumor immunity. Roughly, CD1a+mature LC and DDC sub-
sets have been linked to type-1 T cell mediated immunity, whereas
CD14+ immature DDC subsets have been linked to the induction
of humoral immunity and expansion of regulatory T cells (Treg)
(11, 12); see Figure 1 for a schematic overview. Recent evidence
suggests that tumors like melanoma abuse the balance between
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FIGURE 1 | Overview of the reportedT cell differentiation induction
abilities of mature Langerhans cells (LC) and CD1a+ dermal dendritic
cells (DDC) vs. immature CD14+ DDC. Abbreviations: DDC, dermal
dendritic cell; IL, interleukin; LC, Langerhans cell; Th, T helper cell; Tfh, T
follicular helper cell; Treg, T regulatory cell; TGF-β, transforming growth
factor – β.
these subsets to effectively escape immune recognition (13, 17).
In order for DC-targeted vaccines delivered through the skin to
be effective, tumor-induced immune suppression should be over-
come and T cell-stimulatory DC subsets selectively targeted. Here,
we discuss mechanisms of tumor-imposed DC suppression in the
skin microenvironment and how these may be counter-acted in
aid of DC-based immunotherapy.
LC AND CD1a+ DDC: T CELL ACTIVATION
Klechevsky et al. first described a functional dichotomy between
human LC and CD14+ DDC with the former preferentially acti-
vating CD8+ T cells and the latter B cells (9). In recent publications
primary human LC have been shown to be superior inducers of
Th22 cells (including conventional variant αβ-T cells restricted
through CD1a) (18, 19). IL-22 has an important barrier function
in homeostasis and safeguards the integrity of epithelial layers,
but is also involved in pathological skin conditions like psoriasis.
Furio et al. reported a superior ability of migratory LC over DDC
to induce either Th1 or Th2 responses (20). Of note, DDC in this
report consisted of CD1a−CD14− double-negative DDC with a
potentially lower capacity for T cell activation than CD1a+ DDC.
Mathers and co-workers showed that while LC were superior Th17
inducers, human CD14− DDC had the ability to skew Th cells to
either a Th1, Th2, or Th17 profile, depending on their environ-
mental conditioning, number, and activation state (21). To further
delineate T cell-stimulatory properties of freshly isolated human
LC vs. CD1a+ DDC, we undertook a genome-wide transcrip-
tional profiling analysis which revealed CD1a+ DDC to express
a far wider range of adhesion and co-stimulatory molecules,
chemokines, and cytokines (and at higher levels), pointing to a
putatively superior migratory and T cell stimulatory ability over
LC in steady state conditions (22). Using a human cell line model of
LC and CD1a+ DDC differentiation, we confirmed these data and
showed DDC to be superior activators of cytotoxic CD8+ T cells.
Importantly, this was validated in the same study by a comparative
assessment of the ex vivo ability of human skin-emigrated LC vs.
DDC subsets to prime HLA-A2-matched CD8+ T cells against an
epitope derived from the MART-1 melanoma antigen (23). While
LC and CD1a+ DDC were equally effective in priming allogeneic
Th cells, DDC primed significantly higher rates of MART-1 rec-
ognizing CD8+ T cells at a higher functional avidity. Of note,
Banchereau et al. have recently linked the superior effector CD8+
T cell priming capacity of LC and CD1a+ DDC to their release of
IL-15 into the immunological synapse (12).
CD14+ DDC: T CELL TOLERIZATION
CD14+ migratory DDC are discernable from dermis-resident
CD14+ dermal macrophages through their surface expression of
CD1b and CD1c (24). In a comparative analysis with CD14−DDC,
CD14+ DDC were shown to be poor inducers of allogeneic T cells
and to require high DC:T cell ratios for Th1 induction (25). This
relative inability of CD14+ DDC to induce Th1 cells was related
to their release of IL-10 and TGFβ1. We and others have found
CD14+ DC to carry low levels of co-stimulatory molecules, to dis-
play a poor T cell priming capacity, and to be characterized by the
expression of CD141/BDCA3 (Thrombomodulin), a marker that
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has been linked to a human DC subset with cross-priming ability
(11, 13, 26). These CD14+BDCA3+migratory DDC in a report by
Chu et al. were shown to constitutively release IL-10 and to induce
T cell hyporesponsiveness and Tregs (11). Moreover, they were able
to cross-present self-antigens and inhibit skin inflammation in an
in vivo transplantation model. These data point to an important
role for this subset in T cell homeostasis. Banchereau et al. have
pin-pointed the inability of CD14+ DDC to prime effector CD8+
T cells to their release of IL-10 and TGFβ (12) and the expression
of Ig-like transcript 4 (ILT4) and ILT2 (27).
TUMORS ABUSE DC PLASTICITY TO UNDERMINE
IMMUNITY: A CENTRAL ROLE FOR CD14+ DC
A large number of studies attest to the remarkable plasticity
of the myeloid lineage; tumors abuse this phenotypic plasticity
to re-direct myeloid differentiation toward the development of
immune-suppressive subsets that effectively interfere with anti-
tumor immunity (28). Consequently, tumors are often charac-
terized by an infiltrate of immature macrophage-like cells and a
lack of infiltrating DCs, which is generally a poor prognostic sign
(28). We and others have shown that DC differentiation from
monocytes can be blocked by tumor-derived soluble factors (most
notably IL-10, IL-6, or PGE2) resulting in the development of
CD14+ macrophage-like cells with poor T cell stimulatory abili-
ties (so-called M2-type macrophages) and with T cell suppressive
activity (Figure 2) (29–32). Beside monocytes, fully differenti-
ated DC can be recruited to the tumor microenvironment, where
they may lose their characteristic CD1a expression through the
suppressive action of IL-10, as shown for melanoma metastases
(33). A growing number of studies indicates the unique abil-
ity of tumor-associated IL-10 to convert even fully differentiated
DC to CD14+ suppressive macrophage-like cells (8, 15, 16, 34,
35). IL-10 is generally expressed at high levels in the microen-
vironment of metastatic melanoma and can either be directly
derived from tumor cells or from infiltrating immune cells. Among
a panel of tumor-associated suppressive factors, we found IL-
10 uniquely able to convert DCs to immature macrophage-like
cells in two human model systems: (1) a physiologically highly
relevant skin explant model in which we studied the pheno-
typic and functional traits of “crawl-out” myeloid cells (13) and
(2) an in vitro model of tumor-conditioned DC maturation in
which we functionally assessed CD14− and CD14+ DC that had
developed from monocyte-derived DC (MoDC) during IL-10-
exposed maturation (17). In all above mentioned cases the tumor-
induced M2-like cells shared some striking traits: an immature
CD14+BDCA3+DC-SIGN+CD16+ phenotype and macrophage-
like morphology (Figure 2), a disturbed balance in the release
of immunosuppressive IL-10 (high) vs. immunostimulatory IL-
12p70 (low), high expression levels of the T cell-inhibitory mole-
cule B7-H1/PDL-1, and lower priming efficiency of allogeneic Th
cells and of CD8+ (killer) T cells, the latter specifically recogniz-
ing the melanoma antigen MART-1, but binding epitope/MHC
complexes with low avidity (13, 17, 32, 35).
In studies assessing CD1a and CD14 expression on DC from
human skin explants, we showed the intracutaneous cytokine bal-
ance to be important for the subset composition of migrated
DC (8, 13). Indeed, we have found compelling evidence that LC
and CD1a+ DDC can actually trans-differentiate during and after
FIGURE 2 | Interference by tumor-associated soluble factors with normal
dendritic cell (DC) development through indicated underlying signaling
pathways, leads to (trans-)differentiation of CD14+ M2-macrophage-like
cells with immune-suppressive and tumor growth- and
invasion-promoting properties. Photographic inserts illustrate the DC and
adherent macrophage-like morphology of human skin-emigrated CD83+ and
CD14+ DC, respectively (magnification 400×). Abbreviations: IL, interleukin;
PGE2, prostaglandin-E2.
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migration from human skin explants to a CD14+ macrophage-
like state in an IL-10-dependent fashion. Dermal conditioning
by IL-10 or by topical application of irritants resulted in a shift
among migrated DC from a mature CD83+CD1a+ state to an
immature CD83−CD14+ macrophage-like state, passing through
a CD1a+CD14+ intermediate stage (8, 15). Based on the fact
that these CD14+ cells also expressed CD1c they were classified
as DC rather than macrophages. Moreover, topical application
of irritants to epidermal sheets showed that trans-differentiation
from LC to macrophage-like DC depended on the presence of
dermal fibroblasts and could be blocked by IL-10 neutralizing
antibodies (15). A similar observation has been described in
mice, where the presence of a subcutaneous tumor resulted in
a DC-to-macrophage shift, with macrophage-like cells producing
immune-suppressive factors such as IL-10, iNOS, and Arginase
(16). Importantly, this trans-differentiation among DC that had
migrated from human skin was preventable by co-injection of
the DC-activating cytokines GM-CSF and/or IL-4 prior to skin
explant culture (8).
Consistent with their expression of the M2-macrophage marker
CD163, IL-10-converted CD14+ cells induced IL-10 and FoxP3
mRNA expression in allogeneic Th cells as well as a Th2-
like cytokine profile and Treg expansion (13). Consistent with
these tolerogenic qualities, IL-10-induced CD14+ macrophage-
like MoDCs expressed high levels of immune suppression-related
transcripts such as Indoleamine 2,3-dioxygenase (IDO), IL-4Rα,
IL-6R, TGFβ1, HIF1α, and VEGFA (17). Activation of a HIF1α
transcriptional signature has been reported in tumor-associated
macrophages, even under normoxic conditions (36). This is in line
with the transcriptional and cytokine release profiles we observed
for CD14+ IL-10-conditioned DC, which revealed coordinated
expression of HIF1α, TGFβ, VEGFA, MMP3, MMP9, IL-8, and
TNFα, all of which can contribute to such tumor-promoting
processes as endothelial cell migration and proliferation and
tumor growth and invasion (28). In conclusion, tumor-related
suppressive factors can divert DC during differentiation and even
during and after maturation toward a macrophage-like state with
immune-suppressive and pro-angiogenic and pro-tumor invasive
properties (Figure 2).
Interestingly, in DC migrating from human skin, BDCA3 and
DC-SIGN expression levels showed a very significant inverse cor-
relation with CD83 maturation marker expression, indicating
the utility of these markers for the identification of immature
DC. Indeed, they marked CD14+ skin-emigrated DC as the least
mature population with poor co-stimulatory properties (13). In
keeping with these observations, DC that had migrated from skin
explants taken from breast cancer mastectomy specimens, pre-
dominantly consisted of the CD14+DC subset with a macrophage-
like morphology (13). Normalized distribution (i.e., more mature
and less immature DC subsets) was observed for explants taken
from patients that had received neoadjuvant chemotherapy: a
clear indication that prevailing migration of the immature CD14+
subset was tumor-related.
From our observations we conclude that combined expression
of CD14, BDCA3, DC-SIGN, CD16, and CD163 provides a phe-
notypic profile useful for the identification of M2-macrophage-
like subsets with immune-suppressive and tumor-promoting
characteristics that arise during tumor-conditioned differentiation
or maturation of human DCs. We and others have found evidence
of phenotypically similar subsets in breast, colon, head and neck,
renal cell, and melanoma tumors (17, 37–39). Indeed, in single-
cell suspensions derived from a panel of six metastatic melanoma
tumors, we observed by multicolor flow cytometry analysis, that
CD14+ cells, co-expressing both DC-SIGN and BDCA3 and
detectable in a range of 1–38%, significantly outnumbered CD1a+
DC, which were virtually absent (ranging from 0.05 to 0.1%) (17).
BDCA3 expression has recently been reported on skin-derived
CD14+ DC that induced inflammation-attenuating Tregs (11).
Combined with its association with cross-presenting DC sub-
sets (10), this is highly suggestive of cross-tolerizing ability for
BDCA3+DC. As yet, the functional significance of BDCA3/CD141
in either cross-presentation or immune suppression remains
largely unclear,but some clues are emerging. Its Lectin-like domain
can down-regulate NF-κB and mitogen-activated protein kinase
(MAPK) pathways and might thus interfere with DC maturation
and drive IL-10 release and Th2 skewing (40, 41). In keeping with
this notion, BDCA3+ blood DC promote Th2 skewing (42) and
in vitro generated or skin-derived CD14+BDCA3+ DC release ele-
vated levels of IL-10 (11, 34). In addition, DC-SIGN can negatively
impact DC activation resulting in prolonged and increased IL-10
transcription (43). Both DC-SIGN and BDCA3 may thus con-
tribute to the immune-suppressive activity of tumor-modulated
CD14+ cells.
Recently, the role of non-coding RNAs or microRNAs (miR-
NAs) in myeloid cell plasticity and functionality has also been
studied. In mice, tumor-associated miRNAs were found to modu-
late the survival and longevity of DC (44), miR-223 was described
to negatively regulate and miR-150 to positively regulate the cross-
presenting abilities of LC (45, 46), the TGF-β associated miR-27a
was reported to inhibit DC-mediated differentiation of Th1 and
Th17 cells (47) and in an allergy setting miR-23b was shown
to induce tolerogenic DC through inhibition of the Notch1/NF-
κB pathway (48). In man, this field of research remains largely
unexplored, though miR-155 was shown to regulate the M1/M2-
macrophage balance by targeting the IL13-Receptor α1, thereby
reducing M2 polarization (49).
SIGNAL TRANSDUCTION PATHWAYS ACTING AS MASTER
SWITCHES OF TUMOR-INDUCED DC SUPPRESSION:
TARGETS FOR THERAPEUTIC INTERVENTION
Tumor-derived suppressive factors bind various receptors on
myeloid cells but down-stream signals may converge in shared
pathways. Mostly from mouse studies, the JAK2/STAT3 signal-
ing pathway has emerged as a “master switch” of tumor-induced
immune suppression (50). We have additionally identified p38-
MAPK as an important signaling pathway in human DC sup-
pression, and validated it as such in in vitro DC cultures and
in ex vivo cultures of single-cell suspensions from melanoma
metastases (32). From a panel of tumor-associated suppressive
factors (including PGE2), we found only IL-6 and IL-10 to induce
STAT3 phosphorylation during human MoDC development. As
we had previously identified prostaglandins as the main culprit
of suppressed DC differentiation by supernatants from single-
cell suspensions of metastatic melanoma tumors (29) it was not
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surprising that STAT3 inhibition alone could not prevent this
suppression; for this, combined JAK2/STAT3 and p38-MAPK
inhibition was required. Importantly, combined interference in
the STAT3 and p38 pathways completely prevented inhibition
of DC differentiation by all tested tumor supernatants (n= 18,
derived from both primary tumors and tumor cell lines, together
encompassing eight different histological origins) and led to supe-
rior DC functionality, evidenced by increased allogeneic T cell
reactivity with elevated IL-12p70/IL-10 ratios and Th1 skewing
(32). Most importantly, combined STAT3 and p38 inhibition
supported a shift from CD14+ monocyte-like cells to CD1a+
DC in metastatic melanoma single-cell suspensions, indicating a
potential for improved DC differentiation in the tumor microen-
vironment (32). Of note, siRNA-mediated knockdown of STAT3
only, did effectively prevent the generation of CD14+ cells during
IL-10-modulated MoDC maturation induction (17).
Altogether, these data point to different tumor-associated fac-
tors (i.e., IL-10, IL-6, PGE2) exerting their suppressive effects
at various stages of myeloid DC development through converg-
ing and communicating signaling elements encompassing the
JAK2/STAT3 and p38-MAPK pathways (Figure 2). To specifically
address melanoma-induced myeloid suppression it is important
to further dissect the JAK2/STAT3 and p38-MAPK pathways and
possible cross-talk between them in melanoma-associated myeloid
subsets in order to identify specifically acting and clinically rel-
evant therapeutic targets. The advent of small-molecule kinase
inhibitors and RNAi-based therapeutics now enables targeting
not only of tumors, but also of their stroma, and should facil-
itate re-programing of tumor-associated myeloid cells, as well as
tumor-modulated DC subsets in the skin, in support of anti-tumor
immunity.
THERAPEUTIC ACTIVATION AND TARGETING OF DC IN THE
SKIN AND ITS LYMPH CATCHMENT AREA
Beyond the local suppressive environment at the site of the tumor,
the immune-suppressive effects of the tumor stretch to draining
lymph nodes where anti-tumor T cell responses should be primed.
Sentinel lymph nodes (SLN) are the first-line tumor-draining
lymph nodes and as such bear the brunt of melanoma-induced
immune suppression (51). We have identified and characterized
four conventional DC subsets in melanoma SLN, two of which
were positively identified as skin-derived CD1a+LC and DDC,
and the remaining two (CD1a−CD14− and CD1a−CD14+) as
LN-resident subsets with varying levels of BDCA3 and DC-SIGN
expression (52). Deeper invasion of the primary melanoma in SLN
tumor negative patients was related to a reduced activation state
of skin-derived DC subsets in the SLN (53, 54). Also, lower fre-
quencies of the skin-derived subsets were found in tumor positive
SLN as well as a reduced activation state of LN-resident DC sub-
sets (our own unpublished data). These findings indicate a local
suppressive effect of the primary tumor on the activation state of
skin-derived DC which then migrate to the SLN and lymph node
metastasis-related suppression of SLN-resident DC subsets, and
are in keeping with tumor-induced conditioning of the microen-
vironment (skin or SLN, respectively). Moreover, they suggest
that primary melanoma-mediated suppression of activation and
migration of skin DC enables local metastasis.
In two Phase II clinical trials we have demonstrated that
localized intradermal administration of DC-stimulatory agents
such as GM-CSF and CpG oligodeoxynucleotides (ODN), i.e.,
TLR9 ligands, led to increased activation of DC subsets in SLN
of melanoma patients and tipped the local cytokine balance in
favor of cytotoxic T cell mediated anti-tumor immunity (55–58).
Although in man CpG ODN don’t directly bind to conventional
DC, we nevertheless observed maturation induction of conven-
tional DC subsets, most likely through CpG-induced cytokine
release by plasmacytoid DC (57). In our human skin explant
model we have similarly tested the effects of intradermal deliv-
ery of a panel of TLR-ligands on migratory DC and found a
unique ability of the TLR2 and 3 agonists peptidoglycan (PGN)
and polyriboinosinic-polyribocytidylic acid (Poly I:C) to enhance
the T cell-priming ability of skin-emigrated DC, which, in the case
of PGN, was accompanied by Th1 polarization (59). Surprisingly
only small effects of the tested TLR-ligands on phenotypic DC
activation were observed. This may have been due to induced IL-
10 release, which might have been counter-acted by simultaneous
signaling modulation (60, 61). Indeed, evidence for the therapeu-
tic efficacy of combined STAT3 inhibition and CpG ODN was
previously provided by Kortylewski and colleagues, showing supe-
rior immune stimulatory effects of CpG by eliminating collateral
STAT3-mediated suppressive effects (62, 63).
In conclusion, JAK2/STAT3 and/or p38-MAPK signaling inter-
ference, combined with local immune potentiation, may counter-
balance tumor-imposed suppression of skin DC subsets, minimiz-
ing the induction and trans-differentiation of migratory CD14+
M2-like DC with T cell suppressive characteristics, and thus set
the stage for effective tumor vaccination through DC-targeted
approaches.
AUTHOR CONTRIBUTIONS
Rieneke van de Ven and Tanja D. de Gruijl conceptualized and
wrote the manuscript, Jelle J. Lindenberg and Dinja Oosterhoff
co-wrote the manuscript.
ACKNOWLEDGMENTS
This work was supported by the Netherlands Organization for
Scientific Research, NWO VIDI grant 917–956–321 to Tanja D. de
Gruijl, and Stichting Cancer Center Amsterdam (CCA); Rieneke
van de Ven is a fellow of the Dutch Cancer Society (KWF
BUIT-4643).
REFERENCES
1. Nestle FO, Di Meglio P, Qin J-Z, Nickoloff BJ. Skin immune sentinels in health
and disease. Nat Rev Immunol (2009) 9:679–91. doi:10.1038/nri2622
2. Oosterhoff D, Sluijter BJR, Hangalapura BN, de Gruijl TD. The dermis as a por-
tal for dendritic cell-targeted immunotherapy of cutaneous melanoma. Curr
Top Microbiol Immunol (2012) 351:181–220. doi:10.1007/82_2011_136
3. van der Aar AMG, Sylva-Steenland RMR, Bos JD, Kapsenberg ML, de Jong EC,
Teunissen MBM. Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes
bacterial recognition. J Immunol (2007) 178:1986–90.
4. de Witte L, de Jong MAWP, den Dunnen J, van Kooyk Y, Geijtenbeek TBH.
Identification of pathogen receptors on dendritic cells to understand their func-
tion and to identify new drug targets. Methods Mol Biol (2009) 531:267–85.
doi:10.1007/978-1-59745-396-7_17
5. Unger WW, van Kooyk Y. “Dressed for success” C-type lectin receptors for
the delivery of glyco-vaccines to dendritic cells. Curr Opin Immunol (2011)
23:131–7. doi:10.1016/j.coi.2010.11.011
www.frontiersin.org November 2013 | Volume 4 | Article 403 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
van de Ven et al. Tumor-associated suppression of skin DC
6. Geijtenbeek TBH, Gringhuis SI. Signalling through C-type lectin receptors:
shaping immune responses. Nat Rev Immunol (2009) 9:465–79. doi:10.1038/
nri2569
7. de Gruijl TD, Luykx-de Bakker SA, Tillman BW, van den Eertwegh AJM, Buter J,
Lougheed SM, et al. Prolonged maturation and enhanced transduction of den-
dritic cells migrated from human skin explants after in situ delivery of CD40-
targeted adenoviral vectors. J Immunol (2002) 169:5322–31.
8. de Gruijl TD, Sombroek CC, Lougheed SM, Oosterhoff D, Buter J, van den
Eertwegh AJM, et al. A postmigrational switch among skin-derived dendritic
cells to a macrophage-like phenotype is predetermined by the intracutaneous
cytokine balance. J Immunol (2006) 176:7232–42.
9. Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, Thompson-Snipes L, et al.
Functional specializations of human epidermal Langerhans cells and CD14+
dermal dendritic cells. Immunity (2008) 29:497–510. doi:10.1016/j.immuni.
2008.07.013
10. Haniffa M, Shin A, Bigley V, McGovern N, Teo P, See P, et al. Human tissues
contain CD141hi cross-presenting dendritic cells with functional homology
to mouse CD103+ nonlymphoid dendritic cells. Immunity (2012) 37:60–73.
doi:10.1016/j.immuni.2012.04.012
11. Chu C-C, Ali N, Karagiannis P, Di Meglio P, Skowera A, Napolitano L, et al.
Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and
induce regulatory T cells that suppress skin inflammation. J Exp Med (2012)
209:935–45. doi:10.1084/jem.20112583
12. Banchereau J, Thompson-Snipes L, Zurawski S, Blanck J-P, Cao Y, Clayton
S, et al. The differential production of cytokines by human Langerhans cells
and dermal CD14(+) DCs controls CTL priming. Blood (2012) 119:5742–9.
doi:10.1182/blood-2011-08-371245
13. Lindenberg JJ, Oosterhoff D, Sombroek CC, Lougheed SM, Hooijberg E, Stam
AGM, et al. IL-10 conditioning of human skin affects the distribution of migra-
tory dendritic cell subsets and functional T cell differentiation. PLoS One (2013)
8:e70237. doi:10.1371/journal.pone.0070237
14. Klechevsky E, Banchereau J. Human dendritic cells subsets as targets and vectors
for therapy. Ann N Y Acad Sci (2013) 1284:24–30. doi:10.1111/nyas.12113
15. Ouwehand K, Oosterhoff D, Breetveld M, Scheper RJ, de Gruijl TD, Gibbs
S. Irritant-induced migration of Langerhans cells coincides with an IL-10-
dependent switch to a macrophage-like phenotype. J Invest Dermatol (2011)
131:418–25. doi:10.1038/jid.2010.336
16. Diao J, Mikhailova A, Tang M, Gu H, Zhao J, Cattral MS. Immunostimulatory
conventional dendritic cells evolve into regulatory macrophage-like cells. Blood
(2012) 119:4919–27. doi:10.1182/blood-2011-11-392894
17. Lindenberg JJ, van de Ven R, Lougheed SM, Zomer A, Santegoets SJAM, Grif-
fioen AW, et al. Functional characterization of a STAT3-dependent dendritic
cell-derived CD14(+) cell population arising upon IL-10-driven maturation.
Oncoimmunology (2013) 2:e23837. doi:10.4161/onci.23837
18. Fujita H, Nograles KE, Kikuchi T, Gonzalez J, Carucci JA, Krueger JG. Human
Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17
production. Proc Natl Acad Sci U S A (2009) 106:21795–800. doi:10.1073/pnas.
0911472106
19. de Jong A, Peña-Cruz V, Cheng T-Y, Clark RA, Van Rhijn I, Moody DB. CD1a-
autoreactive T cells are a normal component of the human αβ T cell repertoire.
Nat Immunol (2010) 11:1102–9. doi:10.1038/ni.1956
20. Furio L, Briotet I, Journeaux A, Billard H, Péguet-Navarro J. Human Langer-
hans cells are more efficient than CD14(−)CD1c(+) dermal dendritic cells
at priming naive CD4(+) T cells. J Invest Dermatol (2010) 130:1345–54.
doi:10.1038/jid.2009.424
21. Mathers AR, Janelsins BM, Rubin JP, Tkacheva OA, Shufesky WJ, Watkins SC,
et al. Differential capability of human cutaneous dendritic cell subsets to initiate
Th17 responses. J Immunol (2009) 182:921–33.
22. Santegoets SJAM, Gibbs S, Kroeze K, van de Ven R, Scheper RJ, Borrebaeck
CA, et al. Transcriptional profiling of human skin-resident Langerhans cells and
CD1a+ dermal dendritic cells: differential activation states suggest distinct func-
tions. J Leukoc Biol (2008) 84:143–51. doi:10.1189/jlb.1107750
23. Santegoets SJAM, Bontkes HJ, Stam AGM, Bhoelan F, Ruizendaal JJ, van den
Eertwegh AJM, et al. Inducing antitumor T cell immunity: comparative func-
tional analysis of interstitial versus Langerhans dendritic cells in a human cell
line model. J Immunol (2008) 180:4540–9.
24. Zaba LC, Fuentes-Duculan J, Steinman RM, Krueger JG, Lowes MA. Normal
human dermis contains distinct populations of CD11c+BDCA-1+ dendritic
cells and CD163+FXIIIA+ macrophages. J Clin Invest (2007) 117:2517–25.
doi:10.1172/JCI32282
25. Morelli AE, Rubin JP, Erdos G, Tkacheva OA, Mathers AR, Zahorchak AF, et al.
CD4+ T cell responses elicited by different subsets of human skin migratory
dendritic cells. J Immunol (2005) 175:7905–15.
26. Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X,Angel CE, et al. Human
CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC sub-
set that cross-presents necrotic cell antigens. J Exp Med (2010) 207:1247–60.
doi:10.1084/jem.20092140
27. Banchereau J, Zurawski S, Thompson-Snipes L, Blanck J-P, Clayton S, Munk
A, et al. Immunoglobulin-like transcript receptors on human dermal CD14+
dendritic cells act as a CD8-antagonist to control cytotoxic T cell priming. Proc
Natl Acad Sci U S A (2012) 109:18885–90. doi:10.1073/pnas.1205785109
28. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of
myeloid cells by tumours. Nat Rev Immunol (2012) 12:253–68. doi:10.1038/
nri3175
29. Sombroek CC, Stam AGM, Masterson AJ, Lougheed SM, Schakel MJAG,
Meijer CJLM, et al. Prostanoids play a major role in the primary tumor-
induced inhibition of dendritic cell differentiation. J Immunol (2002) 168:
4333–43.
30. Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, Ramwadhdoebe TH,
Gorter A, Welters MJP, et al. M2 macrophages induced by prostaglandin E2
and IL-6 from cervical carcinoma are switched to activated M1 macrophages
by CD4+ Th1 cells. J Immunol (2011) 187:1157–65. doi:10.4049/jimmunol.
1100889
31. Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P. Positive feed-
back between PGE2 and COX2 redirects the differentiation of human dendritic
cells toward stable myeloid-derived suppressor cells. Blood (2011) 118:5498–505.
doi:10.1182/blood-2011-07-365825
32. Oosterhoff D, Lougheed S, van de Ven R, Lindenberg J, van Cruijsen H,
Hiddingh L, et al. Tumor-mediated inhibition of human dendritic cell
differentiation and function is consistently counteracted by combined p38
MAPK and STAT3 inhibition. Oncoimmunology (2012) 1:649–58. doi:10.4161/
onci.20365
33. Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle FO. Metastatic
melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in
metastatic tumor lesions. Am J Pathol (2004) 165:1853–63. doi:10.1016/S0002-
9440(10)63238-5
34. Velten FW, Duperrier K, Bohlender J, Metharom P, Goerdt S. A gene signature
of inhibitory MHC receptors identifies a BDCA3(+) subset of IL-10-induced
dendritic cells with reduced allostimulatory capacity in vitro. Eur J Immunol
(2004) 34:2800–11. doi:10.1002/eji.200324732
35. Chen F, Hou M, Ye F, Lv W, Xie X. Ovarian cancer cells induce peripheral mature
dendritic cells to differentiate into macrophagelike cells in vitro. Int J Gynecol
Cancer (2009) 19:1487–93. doi:10.1111/IGC.0b013e3181bb70c6
36. Herr B, Zhou J, Werno C, Menrad H, Namgaladze D, Weigert A, et al. The super-
natant of apoptotic cells causes transcriptional activation of hypoxia-inducible
factor-1alpha in macrophages via sphingosine-1-phosphate and transform-
ing growth factor-beta. Blood (2009) 114:2140–8. doi:10.1182/blood-2009-01-
201889
37. Domínguez-Soto A, Sierra-Filardi E, Puig-Kröger A, Pérez-Maceda B, Gómez-
Aguado F, Corcuera MT, et al. Dendritic cell-specific ICAM-3-grabbing non-
integrin expression on M2-polarized and tumor-associated macrophages is
macrophage-CSF dependent and enhanced by tumor-derived IL-6 and IL-10. J
Immunol (2011) 186:2192–200. doi:10.4049/jimmunol.1000475
38. Figel A-M, Brech D, Prinz PU, Lettenmeyer UK, Eckl J, Turqueti-Neves A,
et al. Human renal cell carcinoma induces a dendritic cell subset that uses
T-cell crosstalk for tumor-permissive milieu alterations. Am J Pathol (2011)
179:436–51. doi:10.1016/j.ajpath.2011.03.011
39. Ramanathapuram LV, Hopkin D, Kurago ZB. Dendritic cells (DC) facilitate
detachment of squamous carcinoma cells (SCC), while SCC promote an imma-
ture CD16(+) DC phenotype and control DC migration. Cancer Microenviron
(2013) 6:41–55. doi:10.1007/s12307-011-0077-4
40. Conway EM, Pollefeyt S, Collen D, Steiner-Mosonyi M. The amino terminal
lectin-like domain of thrombomodulin is required for constitutive endocytosis.
Blood (1997) 89:652–61.
41. Bansal K, Sinha AY, Ghorpade DS, Togarsimalemath SK, Patil SA, Kaveri
SV, et al. Src homology 3-interacting domain of Rv1917c of Mycobacterium
Frontiers in Immunology | Tumor Immunity November 2013 | Volume 4 | Article 403 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
van de Ven et al. Tumor-associated suppression of skin DC
tuberculosis induces selective maturation of human dendritic cells by regulat-
ing PI3K-MAPK-NF-kappaB signaling and drives Th2 immune responses. J Biol
Chem (2010) 285:36511–22. doi:10.1074/jbc.M110.158055
42. Yerkovich ST, Roponen M, Smith ME, McKenna K, Bosco A, Subrata LS, et al.
Allergen-enhanced thrombomodulin (blood dendritic cell antigen 3, CD141)
expression on dendritic cells is associated with a TH2-skewed immune response.
J Allergy Clin Immunol (2009) 123:209.e–16.e. doi:10.1016/j.jaci.2008.09.009
43. Gringhuis SI, den Dunnen J, Litjens M, van Het Hof B, van Kooyk Y, Geijtenbeek
TBH. C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-
1 kinase-dependent acetylation of transcription factor NF-kappaB. Immunity
(2007) 26:605–16. doi:10.1016/j.immuni.2007.03.012
44. Min S, Liang X, Zhang M, Zhang Y, Mei S, Liu J, et al. Multiple tumor-associated
microRNAs modulate the survival and longevity of dendritic cells by target-
ing YWHAZ and Bcl2 signaling pathways. J Immunol (2013) 190:2437–46.
doi:10.4049/jimmunol.1202282
45. Mi Q-S, Xu Y-P, Wang H, Qi R-Q, Dong Z, Zhou L. Deletion of microRNA miR-
223 increases Langerhans cell cross-presentation. Int J Biochem Cell Biol (2013)
45:395–400. doi:10.1016/j.biocel.2012.11.004
46. Mi Q-S, Xu Y-P, Qi R-Q, Shi Y-L, Zhou L. Lack of microRNA miR-150 reduces the
capacity of epidermal Langerhans cell cross-presentation. Exp Dermatol (2012)
21:876–7. doi:10.1111/exd.12008
47. Min S, Li L, Zhang M, Zhang Y, Liang X, Xie Y, et al. TGF-β-associated miR-
27a inhibits dendritic cell-mediated differentiation of Th1 and Th17 cells by
TAB3, p38 MAPK, MAP2K4 and MAP2K7. Genes Immun (2012) 13:621–31.
doi:10.1038/gene.2012.45
48. Zheng J, Jiang H-Y, Li J, Tang H-C, Zhang X-M, Wang X-R, et al. MicroRNA-
23b promotes tolerogenic properties of dendritic cells in vitro through inhibit-
ing Notch1/NF-κBsignalling pathways. Allergy (2012) 67:362–70. doi:10.1111/
j.1398-9995.2011.02776.x
49. Martinez-Nunez RT, Louafi F, Sanchez-Elsner T. The interleukin 13 (IL-13)
pathway in human macrophages is modulated by microRNA-155 via direct tar-
geting of interleukin 13 receptor 1 (IL13R 1). J Biol Chem (2011) 286:1786–94.
doi:10.1074/jbc.M110.169367
50. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading
role for STAT3. Nat Rev Cancer (2009) 9:798–809. doi:10.1038/nrc2734
51. Cochran AJ, Huang R-R, Lee J, Itakura E, Leong SPL, Essner R. Tumour-
induced immune modulation of sentinel lymph nodes. Nat Rev Immunol (2006)
6:659–70. doi:10.1038/nri1919
52. van de Ven R, van den Hout MFCM, Lindenberg JJ, Sluijter BJR, van Leeuwen
PAM, Lougheed SM, et al. Characterization of four conventional dendritic cell
subsets in human skin-draining lymph nodes in relation to T-cell activation.
Blood (2011) 118:2502–10. doi:10.1182/blood-2011-03-344838
53. Gerlini G, Di Gennaro P, Mariotti G, Urso C, Chiarugi A, Caporale R, et al.
Human Langerhans cells are immature in melanoma sentinel lymph nodes.
Blood (2012) 119:4807–8. doi:10.1182/blood-2011-12-401067 author reply
4809–10,
54. van den Hout MFCM, Koster BD, Sluijter BJR, van Leeuwen PA, Meijer S, van
den Tol MP, et al. Response: breslow thickness and excision interval affect the
activation state of Langerhans cells in melanoma sentinel lymph nodes. Blood
(2012) 119:4809–10. doi:10.1182/blood-2012-03-413294
55. Vuylsteke RJCLM, Molenkamp BG, Gietema HA, van Leeuwen PAM, Wijnands
PGJTB, Vos W, et al. Local administration of granulocyte/macrophage colony-
stimulating factor increases the number and activation state of dendritic cells
in the sentinel lymph node of early-stage melanoma. Cancer Res (2004)
64:8456–60. doi:10.1158/0008-5472.CAN-03-3251
56. Vuylsteke RJCLM, Molenkamp BG, van Leeuwen PAM, Meijer S, Wijnands
PGJTB, Haanen JBAG, et al. Tumor-specific CD8+ T cell reactivity in the sen-
tinel lymph node of GM-CSF-treated stage I melanoma patients is associated
with high myeloid dendritic cell content. Clin Cancer Res (2006) 12:2826–33.
doi:10.1158/1078-0432.CCR-05-2431
57. Molenkamp BG, van Leeuwen PAM, Meijer S, Sluijter BJR, Wijnands PGJTB,
Baars A, et al. Intradermal CpG-B activates both plasmacytoid and myeloid den-
dritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res
(2007) 13:2961–9. doi:10.1158/1078-0432.CCR-07-0050
58. Molenkamp BG, Sluijter BJR, van Leeuwen PAM, Santegoets SJAM, Meijer S,
Wijnands PGJTB, et al. Local administration of PF-3512676 CpG-B instigates
tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res
(2008) 14:4532–42. doi:10.1158/1078-0432.CCR-07-4711
59. Oosterhoff D, Heusinkveld M, Lougheed SM, Kosten I, Lindstedt M, Bruijns
SCM, et al. Intradermal delivery of TLR agonists in a human explant skin
model: preferential activation of migratory dendritic cells by polyribosinic-
polyribocytidylic acid and peptidoglycans. J Immunol (2013) 190:3338–45.
doi:10.4049/jimmunol.1200598
60. Melillo JA, Song L, Bhagat G, Blazquez AB, Plumlee CR, Lee C, et al. Dendritic
cell (DC)-specific targeting reveals Stat3 as a negative regulator of DC function.
J Immunol (2010) 184:2638–45. doi:10.4049/jimmunol.0902960
61. Oliveira CJF, Carvalho WA, Garcia GR, Gutierrez FRS, de Miranda Santos
IKF, Silva JS, et al. Tick saliva induces regulatory dendritic cells: MAP-kinases
and Toll-like receptor-2 expression as potential targets. Vet Parasitol (2010)
167:288–97. doi:10.1016/j.vetpar.2009.09.031
62. Kortylewski M, Kujawski M, Herrmann A, Yang C, Wang L, Liu Y, et al. Toll-
like receptor 9 activation of signal transducer and activator of transcription 3
constrains its agonist-based immunotherapy. Cancer Res (2009) 69:2497–505.
doi:10.1158/0008-5472.CAN-08-3031
63. Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, Kujawski M,
et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 ago-
nist enhances antitumor immune responses. Nat Biotechnol (2009) 27:925–32.
doi:10.1038/nbt.1564
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 26 September 2013; accepted: 08 November 2013; published online: 25
November 2013.
Citation: van de Ven R, Lindenberg JJ, Oosterhoff D and de Gruijl TD (2013) Dendritic
cell plasticity in tumor-conditioned skin: CD14+ cells at the cross-roads of immune
activation and suppression. Front. Immunol. 4:403. doi: 10.3389/fimmu.2013.00403
This article was submitted to Tumor Immunity, a section of the journal Frontiers in
Immunology.
Copyright © 2013 van de Ven, Lindenberg , Oosterhoff and de Gruijl. This is an open-
access article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
www.frontiersin.org November 2013 | Volume 4 | Article 403 | 7
